HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca et al. · 2007
Read HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients by Marianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001138.txt.
Description
Ovarian cancer often responds well to first chemotherapy, then returns in a drug-resistant form. Marianne Tuefferd and a multicenter French group, GINECO, examined a possible drug target in a 2007 PLOS ONE article. The target is HER2, a growth signal protein already used to guide treatment in breast cancer.
The study measured HER2 status in ovarian cancers from 320 patients. Targeted drugs such as trastuzumab exist for HER2-driven tumors, so knowing how often ovarian cancers carry the marker matters for trial design. The paper gives a large, multi-center count of how common HER2 positivity is in this disease.
Catalog record
| CREATOR | Marianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca et al. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001138